Efficacy of recombinant human endostatin combined with pericardial perfusion of cisplatin on non-small cell lung cancer patients with malignant pericardial effusion
Objective To observe the efficacy of recombinant human endostatin combined with pericardial perfusion of cisplatin on non-small cell lung cancer(NSCLC)patients with malignant pericardial effusion(MPCE).Methods A total of 77 NSCLC patients with MPCE were randomly divided into recombinant human endostatin group(trade name:Endostar;n= 26),cisplatin group(n=24)and Endostar + cisplatin group(n=27).All patients in the three groups were managed by would be underwent pericardiocentesis with a central venous catheter indwelled in the pericardial cavity.They were intrapericardially perfused with recombinant human endostatin,cisplatin and their combination in the three groups,respectively.The efficacy and adverse events were compared among the three groups.Results There was a significant difference in the efficacy of recombinant human endostatin,cisplatin and their combination on NSCLC patients with MPCE(P<0.05),which gradually increased in the three groups.The incidence of adverse events in the Endostar group and Endostar + cisplatin group was significantly lower than that of cisplatin group(P<0.05),which was comparable between the former two groups(P>0.05).Conclusion Recombinant human endostatin combined with pericardial perfusion of cisplatin has a good efficacy on NSCLC patients with MPCE,with a low incidence of adverse events.
万方数据
维普
